We propose that patients with increased systemic vascular resistance secondary to increased angiotensin II, such as those with systolic heart failure, liver cirrhosis or volume depletion may be at increased risk of systemic hypotension when taking thiazide derivatives. The gene discussed is AGT; the disease is systolic heart failure.